- Trials with a EudraCT protocol (1,742)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
1,742 result(s) found for: Group testing.
Displaying page 1 of 88.
EudraCT Number: 2005-001622-91 | Sponsor Protocol Number: RKMMS 04 | Start Date*: 2005-06-23 |
Sponsor Name:Royal Group Hospitals | ||
Full Title: A randomised assessor blinded study to examine the role of skin testing in the prediction of peri-operative anaphylaxis and its correlation with mast cell tryptase and total IgE. | ||
Medical condition: Prevalance of sensitivity of immune system to the four named neuromuscular blocking drugs in patients undergoing anaesthesia. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2006-004199-11 | Sponsor Protocol Number: NOSTRADAMUS | Start Date*: 2007-02-16 | |||||||||||
Sponsor Name:Academic Medical Center | |||||||||||||
Full Title: NOSTRADAMUS: Testing for thrombophilia in patients with a first episode of venous thromboembolism: a randomized controlled trial to assess effects on clinical outcomes, quality of life, and costs. | |||||||||||||
Medical condition: A randomized controlled trial of testing and no testing for thrombophilia in patients with a first episode of venous thrombosis or pulmonary embolism (venous thromboembolism, VTE) will be performed... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002894-36 | Sponsor Protocol Number: IXIARO-booster-senescence | Start Date*: 2017-12-22 |
Sponsor Name:Medical University of Vienna (MUW) | ||
Full Title: "An open, monocentric, uncontrolled phase 4 trial to characterise cellular and humoral immune responses following the first booster immunisation with the inactivated, purified Japanese Encephalitis... | ||
Medical condition: The condition under investigation is the naturally aging immune system. The aim of this study is to investigate the immune responses following a booster immunisation with the Japanese Encephalitis ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-003514-39 | Sponsor Protocol Number: GNCbumet | Start Date*: Information not available in EudraCT |
Sponsor Name:Gillberg Neuropsychiatry Centre | ||
Full Title: Testing E/I imbalance in autism with Bumetanide – a parallel group randomized waitlist-control trial in adolescents and adults | ||
Medical condition: Autism Spectrum Disorder | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001013-41 | Sponsor Protocol Number: CIGE025A2210 | Start Date*: 2008-01-18 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double-blind, placebo-controlled study to demonstrate the efficacy of Xolair in an allergen bronchoprovocation study in two asthmatic populations defined by serum IgE concentrations | ||
Medical condition: Asthma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-000757-31 | Sponsor Protocol Number: 2018/728 | Start Date*: 2019-08-30 |
Sponsor Name:Martina Hansens Hospital | ||
Full Title: A RANDOMIZED PLACEBO CONTROLLED TRIAL TESTING THE EFFECTS OF ZOLEDRONIC ACID ON HIP OSTEOARTHRITIS | ||
Medical condition: Investigated disease is osteoarthritis of the hip with concurrent Bone marrow lesions | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004547-77 | Sponsor Protocol Number: RN03-CP-0001 | Start Date*: 2020-06-09 | |||||||||||
Sponsor Name:ReNeuron Ltd | |||||||||||||
Full Title: First-in-human Phase I/IIa, Open-Label, Prospective Study of the Safety and Tolerability of Subretinally Transplanted Human Retinal Progenitor Cells (hRPC) in Subjects with Retinitis Pigmentosa (RP) | |||||||||||||
Medical condition: Retinitis Pigmentosa | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-000684-26 | Sponsor Protocol Number: CVAH631B2406 | Start Date*: 2006-03-03 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A randomized, double blind, parallel group, active-controlled, multi-center, 14 week study to evaluate the effectiveness of a valsartan versus an amlodipine treatment stratgey in achieving blood pr... | ||
Medical condition: Essential hypertension | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) ES (Completed) IT (Completed) FI (Completed) DK (Completed) IE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000539-27 | Sponsor Protocol Number: CLAF237A2307 | Start Date*: 2004-09-08 |
Sponsor Name:Novartis Sverige AB | ||
Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 52 Weeks Treatment with LAF237 50 mg qd to Placebo in Drug-Naïve Patients with Type 2 Diabetes and Mild Hyperg... | ||
Medical condition: Type 2 Diabetes | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) FI (Completed) ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-001450-26 | Sponsor Protocol Number: LAX-01 | Start Date*: 2019-06-28 | |||||||||||
Sponsor Name:Institute for Public Health and Caring Sciences, Uppsala University | |||||||||||||
Full Title: Can the experience of a diminished effect of local anesthetics be verified by an objective test? | |||||||||||||
Medical condition: Local anesthetics for minor or more major procedures such as suturing lacerations, removing skin lesions, operating ingrown toenails, drilling and removing teeth etc. | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002109-20 | Sponsor Protocol Number: AAV2-hRPE65v2-301 | Start Date*: 2016-10-24 | |||||||||||
Sponsor Name:Spark Therapeutics, Inc. | |||||||||||||
Full Title: A Safety and Efficacy Study in Subjects with Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 to the Retinal Pigment Epithelium (RPE) [AAV2-h... | |||||||||||||
Medical condition: Leber Congenital Amaurosis (LCA) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004741-37 | Sponsor Protocol Number: 212458 | Start Date*: 2021-06-21 |
Sponsor Name:GlaxoSmithKline Biologicals | ||
Full Title: A Phase I/II, randomised, controlled study to assess the safety, effectiveness and immune response of meningococcal combined ABCWY vaccine when administered to healthy adults (Phase I) and to healt... | ||
Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) FI (Completed) Outside EU/EEA PL (Completed) SE (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-005682-13 | Sponsor Protocol Number: 76061 | Start Date*: 2021-04-22 |
Sponsor Name:Radboudumc | ||
Full Title: Exploratory study into age-related immunological differences related to immunogenicity in influenza vaccination and herpes zoster vaccination | ||
Medical condition: Influenza Herpes Zoster | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2010-020840-36 | Sponsor Protocol Number: V98_04 | Start Date*: 2011-08-08 | |||||||||||
Sponsor Name:Novartis Vaccines and Diagnostics GmbH | |||||||||||||
Full Title: A Phase II Randomized, Observer-Blind, Multi-Center, Controlled Study of a Trivalent group B Streptococcus Vaccine in Healthy Pregnant Women | |||||||||||||
Medical condition: Invasive group B streptococcus disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023375-26 | Sponsor Protocol Number: SYDNEY_Sildenafil_Version_1.8.2011 | Start Date*: 2012-06-27 |
Sponsor Name:Medizinische Universität Wien, Klinik für Innere Medizin II, Abteilung für Kardiologie | ||
Full Title: Effects of Sildenafil on Signs and SYmptoms of Ischemia, Myocardial BlooD Flow, and Markers of ANgiogenesis in Patients with REfractory CoronarY Artery Disease (SYDNEY) A Randomized, Double-Blind,... | ||
Medical condition: Patients with coronary artery disease who suffer from myocardial malperfusion and continue to experience angina despite maximal medical and revascularization therapy are called "no-option" patients. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2015-000962-76 | Sponsor Protocol Number: 17992 | Start Date*: 2015-09-22 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: Single-dose study testing a rivaroxaban granules for oral suspension formulation in children from 2 months to 12 years with previous thrombosis | |||||||||||||
Medical condition: Thrombosis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) BE (Completed) IE (Completed) ES (Completed) FI (Completed) HU (Completed) SE (Completed) FR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000691-11 | Sponsor Protocol Number: 89303200 | Start Date*: 2022-01-18 |
Sponsor Name:Rigshospitalet | ||
Full Title: Comparison of the effect of xylometazoline and cocaine on epistaxis when administered as local vasoconstrictors prior to nasal intubation | ||
Medical condition: Epistaxis upon nasal intubation | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005534-12 | Sponsor Protocol Number: AVH-2004/1 | Start Date*: 2006-04-18 |
Sponsor Name:The Symbio Herborn Group GmbH | ||
Full Title: randomized double blind placebo controlled study on the efficacy of autologous autovaccine in house dust mite allergy | ||
Medical condition: Allergic diseases such as rhinoconjunctivitis or bronchial asthma are a major public health burden. The huge associated costs demand an evidence based therapeutic aproach. The only available causat... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001670-33 | Sponsor Protocol Number: 215344 | Start Date*: 2022-02-07 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A Phase IIb, Randomized, Observer-Blind study to Describe the Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents | |||||||||||||
Medical condition: Healthy volunteers (Active immunization against IMD caused by N.meningitidis serogroups A, B, C, W and Y) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001367-24 | Sponsor Protocol Number: 217043 | Start Date*: 2021-11-16 | |||||||||||
Sponsor Name:GlaxoSmithKline SA | |||||||||||||
Full Title: A Phase II, randomized, partially blinded study to assess the safety, tolerability and immunogenicity of meningococcal combined ABCWY vaccine when administered to healthy infants. | |||||||||||||
Medical condition: Healthy volunteers (Active immunization against IMD caused by Neisseria Meningitidis (N.meningitidis) serogroups A, B, C, W and Y) | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Temporarily Halted) DE (Trial now transitioned) PL (Trial now transitioned) IT (Completed) FI (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
